25 XP   0   0   10

ContraFect Corp
Buy, Hold or Sell?

Let's analyse Contrafect together

PenkeI guess you are interested in ContraFect Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ContraFect Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about ContraFect Corp

I send you an email if I find something interesting about ContraFect Corp.

Quick analysis of Contrafect (30 sec.)










What can you expect buying and holding a share of Contrafect? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.54
Expected worth in 1 year
$-0.79
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-0.25
Return On Investment
-915.5%

For what price can you sell your share?

Current Price per Share
$0.03
Expected price per share
$0.025 - $0.0399
How sure are you?
50%

1. Valuation of Contrafect (5 min.)




Live pricePrice per Share (EOD)

$0.03

Intrinsic Value Per Share

$-34.09 - $-27.31

Total Value Per Share

$-34.63 - $-27.84

2. Growth of Contrafect (5 min.)




Is Contrafect growing?

Current yearPrevious yearGrowGrow %
How rich?-$5.7m$22.2m-$27.7m-507.9%

How much money is Contrafect making?

Current yearPrevious yearGrowGrow %
Making money-$5.5m-$13.7m$8.1m148.9%
Net Profit Margin0.0%-300.8%--

How much money comes from the company's main activities?

3. Financial Health of Contrafect (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#946 / 1031

Most Revenue
#945 / 1031

Most Profit
#480 / 1031

Most Efficient
#426 / 1031

What can you expect buying and holding a share of Contrafect? (5 min.)

Welcome investor! Contrafect's management wants to use your money to grow the business. In return you get a share of Contrafect.

What can you expect buying and holding a share of Contrafect?

First you should know what it really means to hold a share of Contrafect. And how you can make/lose money.

Speculation

The Price per Share of Contrafect is $0.0271. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Contrafect.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Contrafect, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.54. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.31 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Contrafect.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.50-1,847.3%-0.66-2,418.4%-1.39-5,140.6%-0.65-2,389.0%-0.76-2,816.6%
Usd Book Value Change Per Share-0.43-1,603.2%-0.06-228.9%-1.31-4,835.2%-0.02-87.2%-0.03-115.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.43-1,603.2%-0.06-228.9%-1.31-4,835.2%-0.02-87.2%-0.03-115.6%
Usd Price Per Share0.57-1.00-2.38-2.63-2.54-
Price to Earnings Ratio-0.28--0.37--0.65--0.58--0.55-
Price-to-Total Gains Ratio-1.31-2.18--2.95--0.63--0.32-
Price to Book Ratio-1.06--5.47-0.96-0.44--0.11-
Price-to-Total Gains Ratio-1.31-2.18--2.95--0.63--0.32-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0271
Number of shares36900
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.06-0.02
Usd Total Gains Per Share-0.06-0.02
Gains per Quarter (36900 shares)-2,288.84-871.70
Gains per Year (36900 shares)-9,155.36-3,486.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9155-91650-3487-3497
20-18311-183200-6974-6984
30-27466-274750-10460-10471
40-36621-366300-13947-13958
50-45777-457850-17434-17445
60-54932-549400-20921-20932
70-64088-640950-24408-24419
80-73243-732500-27894-27906
90-82398-824050-31381-31393
100-91554-915600-34868-34880

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%4.036.00.010.0%4.039.01.09.1%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%8.012.00.040.0%16.024.00.040.0%17.024.03.038.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.044.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%8.012.00.040.0%16.024.00.040.0%17.024.03.038.6%

Fundamentals of Contrafect

About ContraFect Corp

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Fundamental data was last updated by Penke on 2024-03-20 13:15:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of ContraFect Corp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Contrafect earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Contrafect to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ContraFect Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-300.8%+300.8%
TTM-5Y-73.4%+73.4%
5Y-73.4%10Y-37.8%-35.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--205.8%+205.8%
YOY-300.8%-262.1%-38.7%
5Y-73.4%-455.6%+382.2%
10Y-37.8%-589.0%+551.2%
1.1.2. Return on Assets

Shows how efficient Contrafect is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Contrafect to the Biotechnology industry mean.
  • -58.7% Return on Assets means that Contrafect generated $-0.59 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ContraFect Corp:

  • The MRQ is -58.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -35.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-58.7%TTM-35.5%-23.3%
TTM-35.5%YOY-35.0%-0.5%
TTM-35.5%5Y-20.3%-15.1%
5Y-20.3%10Y-25.4%+5.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-58.7%-12.5%-46.2%
TTM-35.5%-12.2%-23.3%
YOY-35.0%-11.2%-23.8%
5Y-20.3%-13.4%-6.9%
10Y-25.4%-14.7%-10.7%
1.1.3. Return on Equity

Shows how efficient Contrafect is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Contrafect to the Biotechnology industry mean.
  • 0.0% Return on Equity means Contrafect generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ContraFect Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-54.1%+54.1%
TTM-5Y-30.1%+30.1%
5Y-30.1%10Y-41.5%+11.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.8%+15.8%
TTM--15.7%+15.7%
YOY-54.1%-13.9%-40.2%
5Y-30.1%-18.3%-11.8%
10Y-41.5%-19.2%-22.3%

1.2. Operating Efficiency of ContraFect Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Contrafect is operating .

  • Measures how much profit Contrafect makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Contrafect to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ContraFect Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-418.5%+418.5%
TTM-5Y-87.9%+87.9%
5Y-87.9%10Y-45.6%-42.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM--210.1%+210.1%
YOY-418.5%-279.7%-138.8%
5Y-87.9%-459.9%+372.0%
10Y-45.6%-596.9%+551.3%
1.2.2. Operating Ratio

Measures how efficient Contrafect is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ContraFect Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY3.449-3.449
TTM-5Y0.731-0.731
5Y0.73110Y0.383+0.348
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM-3.193-3.193
YOY3.4493.615-0.166
5Y0.7315.560-4.829
10Y0.3837.396-7.013

1.3. Liquidity of ContraFect Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Contrafect is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.53 means the company has $0.53 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ContraFect Corp:

  • The MRQ is 0.529. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.820. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.529TTM0.820-0.291
TTM0.820YOY2.748-1.928
TTM0.8205Y4.544-3.724
5Y4.54410Y5.732-1.188
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5293.986-3.457
TTM0.8204.440-3.620
YOY2.7485.552-2.804
5Y4.5446.158-1.614
10Y5.7326.492-0.760
1.3.2. Quick Ratio

Measures if Contrafect is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Contrafect to the Biotechnology industry mean.
  • A Quick Ratio of 0.44 means the company can pay off $0.44 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ContraFect Corp:

  • The MRQ is 0.439. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.814. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.439TTM0.814-0.375
TTM0.814YOY3.940-3.126
TTM0.8145Y6.175-5.361
5Y6.17510Y8.609-2.434
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4393.638-3.199
TTM0.8144.168-3.354
YOY3.9405.515-1.575
5Y6.1756.012+0.163
10Y8.6096.209+2.400

1.4. Solvency of ContraFect Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Contrafect assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Contrafect to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.63 means that Contrafect assets are financed with 163.1% credit (debt) and the remaining percentage (100% - 163.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ContraFect Corp:

  • The MRQ is 1.631. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.354. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.631TTM1.354+0.278
TTM1.354YOY0.636+0.718
TTM1.3545Y0.750+0.603
5Y0.75010Y0.847-0.097
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6310.335+1.296
TTM1.3540.330+1.024
YOY0.6360.267+0.369
5Y0.7500.367+0.383
10Y0.8470.378+0.469
1.4.2. Debt to Equity Ratio

Measures if Contrafect is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Contrafect to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ContraFect Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.847-0.847
TTM-5Y1.368-1.368
5Y1.36810Y1.125+0.243
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM-0.398-0.398
YOY0.8470.334+0.513
5Y1.3680.429+0.939
10Y1.1250.476+0.649

2. Market Valuation of ContraFect Corp

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Contrafect generates.

  • Above 15 is considered overpriced but always compare Contrafect to the Biotechnology industry mean.
  • A PE ratio of -0.28 means the investor is paying $-0.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ContraFect Corp:

  • The EOD is -0.014. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.285. Based on the earnings, the company is expensive. -2
  • The TTM is -0.374. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.014MRQ-0.285+0.271
MRQ-0.285TTM-0.374+0.089
TTM-0.374YOY-0.647+0.273
TTM-0.3745Y-0.576+0.202
5Y-0.57610Y-0.550-0.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.014-2.643+2.629
MRQ-0.285-2.418+2.133
TTM-0.374-2.742+2.368
YOY-0.647-4.123+3.476
5Y-0.576-6.257+5.681
10Y-0.550-6.478+5.928
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ContraFect Corp:

  • The EOD is -0.008. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.176. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.312. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.008MRQ-0.176+0.168
MRQ-0.176TTM-0.312+0.136
TTM-0.312YOY-0.565+0.253
TTM-0.3125Y-0.776+0.463
5Y-0.77610Y-0.950+0.174
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.008-3.244+3.236
MRQ-0.176-2.939+2.763
TTM-0.312-3.478+3.166
YOY-0.565-5.592+5.027
5Y-0.776-8.473+7.697
10Y-0.950-8.881+7.931
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Contrafect is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -1.06 means the investor is paying $-1.06 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ContraFect Corp:

  • The EOD is -0.050. Based on the equity, the company is expensive. -2
  • The MRQ is -1.060. Based on the equity, the company is expensive. -2
  • The TTM is -5.471. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.050MRQ-1.060+1.009
MRQ-1.060TTM-5.471+4.411
TTM-5.471YOY0.961-6.432
TTM-5.4715Y0.443-5.914
5Y0.44310Y-0.110+0.553
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0502.124-2.174
MRQ-1.0602.041-3.101
TTM-5.4712.118-7.589
YOY0.9612.915-1.954
5Y0.4433.682-3.239
10Y-0.1104.114-4.224
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ContraFect Corp.

3.1. Institutions holding ContraFect Corp

Institutions are holding 6.133% of the shares of ContraFect Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Armistice Capital, LLC4.43730.0042475000419258752.1402
2023-09-30Geode Capital Management, LLC0.22023547235470
2023-09-30Virtu Financial LLC0.21920.001423469234690
2023-09-30TWO SIGMA SECURITIES, LLC0.19660.000121047787059.7253
2023-09-30Acadian Asset Management LLC0.1645017608176080
2023-09-30Vanguard Group Inc0.152301630400
2023-09-30Tower Research Capital LLC0.09510.000210182309943.7526
2023-09-30BlackRock Inc0.049805329-38-0.708
2023-09-30Royal Bank of Canada0.002502718747.2826
2023-09-30Morgan Stanley - Brokerage Accounts0.0011011900
2023-09-30JPMorgan Chase & Co0.000606200
2023-09-30Wells Fargo & Co0.000302716145.4545
2023-09-30Bank of America Corp0.00010600
2023-09-30FMR Inc00220
2023-09-30UBS Group AG002-2519-99.9207
2023-09-30Group One Trading, LP002-231-99.1416
2023-12-31Central Bank & Trust Co (Lexington, KY)000-14-100
2023-12-31Washington Trust Advisors, Inc.000-5-100
2023-12-31Carmichael Hill & Associates Inc000-2-100
Total 5.53940.0059592977+492147+83.0%

3.2. Funds holding ContraFect Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30BlackRock Extended Mkt Composite0.01490159800
2023-09-30Stewart Capital Mid Cap Portfolio0.000505300
Total 0.01540165100.0%

3.3. Insider Transactions

Insiders are holding 0.652% of the shares of ContraFect Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2019-12-13Cary SucoffBUY500000.3962000
2019-12-13Michael MessingerBUY50000.3719091
2018-12-04Fosun Pharmaceutical ShanghaiSELL6000002.047900000
2017-07-25Cara M CassinoBUY80001.248000
2017-07-25Joshua B MuntnerBUY20001.242000
2017-07-25Sol J BarerBUY400001.24815933
2017-07-25Steven C GilmanBUY8001.2420800
2016-07-27Steven C GilmanBUY200002.4820000
2015-11-17Daniel CoutoSELL28723.81
2015-11-03Daniel CoutoSELL28674.232872
2015-10-20Daniel CoutoSELL28674.485739
2015-10-06Daniel CoutoSELL28674.118606
2015-09-22Daniel CoutoSELL28674.7610773
2015-09-08Daniel CoutoSELL28674.914340
2015-03-02Julia P GregoryBUY117784.61

4. Summary

4.1. Key Performance Indicators

The key performance indicators of ContraFect Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.434-0.062-86%-1.310+202%-0.024-95%-0.031-93%
Book Value Per Share---0.538-0.510-5%2.082-126%1.614-133%1.417-138%
Current Ratio--0.5290.820-36%2.748-81%4.544-88%5.732-91%
Debt To Asset Ratio--1.6311.354+21%0.636+156%0.750+117%0.847+93%
Debt To Equity Ratio----0%0.847-100%1.368-100%1.125-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.501-0.655+31%-1.393+178%-0.647+29%-0.763+52%
Free Cash Flow Per Share---0.810-0.833+3%-1.041+29%-0.843+4%-0.686-15%
Free Cash Flow To Equity Per Share---0.842-0.283-66%-2.096+149%0.595-241%0.480-275%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---27.306--------
Intrinsic Value_10Y_min---34.089--------
Intrinsic Value_1Y_max---2.748--------
Intrinsic Value_1Y_min---3.714--------
Intrinsic Value_3Y_max---8.248--------
Intrinsic Value_3Y_min---10.966--------
Intrinsic Value_5Y_max---13.737--------
Intrinsic Value_5Y_min---17.953--------
Market Cap290100.080-2003%6101737.71010694095.628-43%25472071.600-76%28186006.106-78%27138193.477-78%
Net Profit Margin----0%-3.0080%-0.7340%-0.3780%
Operating Margin----0%-4.1850%-0.8790%-0.4560%
Operating Ratio----0%3.449-100%0.731-100%0.383-100%
Pb Ratio-0.050+95%-1.060-5.471+416%0.961-210%0.443-339%-0.110-90%
Pe Ratio-0.014+95%-0.285-0.374+31%-0.647+127%-0.576+102%-0.550+93%
Price Per Share0.027-2003%0.5700.999-43%2.380-76%2.633-78%2.535-78%
Price To Free Cash Flow Ratio-0.008+95%-0.176-0.312+78%-0.565+221%-0.776+341%-0.950+440%
Price To Total Gains Ratio-0.062+95%-1.3122.183-160%-2.952+125%-0.634-52%-0.320-76%
Quick Ratio--0.4390.814-46%3.940-89%6.175-93%8.609-95%
Return On Assets---0.587-0.355-40%-0.350-40%-0.203-65%-0.254-57%
Return On Equity----0%-0.5410%-0.3010%-0.4150%
Total Gains Per Share---0.434-0.062-86%-1.310+202%-0.024-95%-0.031-93%
Usd Book Value---5759000.000-5464000.000-5%22289000.000-126%17276043.850-133%15171734.675-138%
Usd Book Value Change Per Share---0.434-0.062-86%-1.310+202%-0.024-95%-0.031-93%
Usd Book Value Per Share---0.538-0.510-5%2.082-126%1.614-133%1.417-138%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.501-0.655+31%-1.393+178%-0.647+29%-0.763+52%
Usd Free Cash Flow---8669000.000-8912250.000+3%-11143504.750+29%-9023550.600+4%-7348469.150-15%
Usd Free Cash Flow Per Share---0.810-0.833+3%-1.041+29%-0.843+4%-0.686-15%
Usd Free Cash Flow To Equity Per Share---0.842-0.283-66%-2.096+149%0.595-241%0.480-275%
Usd Market Cap290100.080-2003%6101737.71010694095.628-43%25472071.600-76%28186006.106-78%27138193.477-78%
Usd Price Per Share0.027-2003%0.5700.999-43%2.380-76%2.633-78%2.535-78%
Usd Profit---5359000.000-5506750.000+3%-13705000.000+156%-6387223.500+19%-7040550.775+31%
Usd Revenue----0%8438000.000-100%2417393.600-100%1484849.275-100%
Usd Total Gains Per Share---0.434-0.062-86%-1.310+202%-0.024-95%-0.031-93%
 EOD+2 -6MRQTTM+7 -20YOY+17 -135Y+10 -2010Y+7 -23

4.2. Fundamental Score

Let's check the fundamental score of ContraFect Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.014
Price to Book Ratio (EOD)Between0-1-0.050
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.439
Current Ratio (MRQ)Greater than10.529
Debt to Asset Ratio (MRQ)Less than11.631
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.587
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of ContraFect Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.685
Ma 20Greater thanMa 500.032
Ma 50Greater thanMa 1000.037
Ma 100Greater thanMa 2000.196
OpenGreater thanClose0.030
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets9,125
Total Liabilities14,884
Total Stockholder Equity-5,759
 As reported
Total Liabilities 14,884
Total Stockholder Equity+ -5,759
Total Assets = 9,125

Assets

Total Assets9,125
Total Current Assets6,520
Long-term Assets2,605
Total Current Assets
Cash And Cash Equivalents 5,413
Other Current Assets 12
Total Current Assets  (as reported)6,520
Total Current Assets  (calculated)5,425
+/- 1,095
Long-term Assets
Property Plant Equipment 2,500
Long-term Assets Other 105
Long-term Assets  (as reported)2,605
Long-term Assets  (calculated)2,605
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,323
Long-term Liabilities2,561
Total Stockholder Equity-5,759
Total Current Liabilities
Short-term Debt 680
Accounts payable 8,179
Other Current Liabilities 3,464
Total Current Liabilities  (as reported)12,323
Total Current Liabilities  (calculated)12,323
+/-0
Long-term Liabilities
Capital Lease Obligations 2,553
Long-term Liabilities  (as reported)2,561
Long-term Liabilities  (calculated)2,553
+/- 8
Total Stockholder Equity
Common Stock1
Retained Earnings -340,003
Other Stockholders Equity 334,243
Total Stockholder Equity (as reported)-5,759
Total Stockholder Equity (calculated)-5,759
+/-0
Other
Capital Stock1
Cash and Short Term Investments 5,413
Common Stock Shares Outstanding 10,705
Liabilities and Stockholders Equity 9,125
Net Debt -2,860
Net Invested Capital -5,759
Net Working Capital -5,803
Property Plant and Equipment Gross 2,500
Short Long Term Debt Total 2,553



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
13,206
0
0
0
9,684
8,684
7,985
34,201
30,054
25,310
38,342
32,297
35,861
29,036
22,211
45,873
37,624
31,749
25,293
55,124
50,189
43,162
36,953
40,876
32,873
29,948
20,917
17,443
35,009
26,429
67,706
59,996
51,116
96,630
86,807
77,842
66,762
56,040
40,798
23,034
20,679
20,552
19,252
9,125
9,12519,25220,55220,67923,03440,79856,04066,76277,84286,80796,63051,11659,99667,70626,42935,00917,44320,91729,94832,87340,87636,95343,16250,18955,12425,29331,74937,62445,87322,21129,03635,86132,29738,34225,31030,05434,2017,9858,6849,68400013,206
   > Total Current Assets 
0
0
0
0
4,344
4,624
2,442
31,737
27,762
23,153
36,319
30,408
34,099
27,376
20,557
44,362
36,179
30,349
23,939
53,812
48,702
41,668
35,496
39,404
31,441
25,147
16,215
12,842
30,760
22,283
44,979
56,063
47,289
91,239
76,032
73,873
62,864
52,272
37,712
20,049
17,706
17,698
16,514
6,520
6,52016,51417,69817,70620,04937,71252,27262,86473,87376,03291,23947,28956,06344,97922,28330,76012,84216,21525,14731,44139,40435,49641,66848,70253,81223,93930,34936,17944,36220,55727,37634,09930,40836,31923,15327,76231,7372,4424,6244,3440000
       Cash And Cash Equivalents 
7,886
0
0
0
4,145
4,419
2,194
31,320
25,722
12,355
23,642
20,844
9,973
7,639
10,592
10,665
3,807
4,715
4,879
4,298
6,995
3,471
4,570
10,955
8,320
6,826
7,377
10,502
24,184
10,632
30,819
18,152
15,485
65,246
21,406
20,225
16,654
9,637
9,549
4,664
8,907
11,866
14,422
5,413
5,41314,42211,8668,9074,6649,5499,63716,65420,22521,40665,24615,48518,15230,81910,63224,18410,5027,3776,8268,32010,9554,5703,4716,9954,2984,8794,7153,80710,66510,5927,6399,97320,84423,64212,35525,72231,3202,1944,4194,1450007,886
       Short-term Investments 
0
0
0
0
0
0
0
0
1,671
10,526
11,622
8,618
22,949
18,627
8,500
32,548
31,354
24,173
16,830
48,255
39,859
36,380
28,724
26,645
22,132
16,268
6,852
0
0
6,019
8,832
32,083
27,005
20,904
46,093
43,092
37,631
32,644
17,753
12,984
4,775
2,025
0
0
002,0254,77512,98417,75332,64437,63143,09246,09320,90427,00532,0838,8326,019006,85216,26822,13226,64528,72436,38039,85948,25516,83024,17331,35432,5488,50018,62722,9498,61811,62210,5261,67100000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
343
429
498
564
202
355
600
355
105
105
1,000
105
1,100
1,400
3,800
4,419
613
601
2,097
586
2,600
1,700
571
0
05711,7002,6005862,0976016134,4193,8001,4001,1001051,00010510535560035520256449842934300000000000000000000
   > Long-term Assets 
0
0
0
0
5,340
4,060
5,542
2,464
2,292
2,157
2,023
1,889
1,763
1,660
1,655
1,512
1,446
1,400
1,355
1,313
1,488
1,494
1,458
1,473
1,432
4,801
4,702
4,601
4,249
4,145
22,727
3,933
3,826
5,391
10,775
3,969
3,898
3,768
3,086
2,985
2,973
2,854
2,738
2,605
2,6052,7382,8542,9732,9853,0863,7683,8983,96910,7755,3913,8263,93322,7274,1454,2494,6014,7024,8011,4321,4731,4581,4941,4881,3131,3551,4001,4461,5121,6551,6601,7631,8892,0232,1572,2922,4645,5424,0605,3400000
       Property Plant Equipment 
3,308
0
0
0
2,735
2,596
2,456
2,320
2,148
2,014
1,879
1,745
1,619
1,516
1,490
1,347
1,281
1,236
1,190
1,148
1,094
1,139
1,102
1,117
1,076
4,445
4,346
4,246
4,144
4,040
3,934
3,828
3,721
3,621
3,509
3,398
3,285
3,167
2,979
2,877
2,868
2,749
2,633
2,500
2,5002,6332,7492,8682,8772,9793,1673,2853,3983,5093,6213,7213,8283,9344,0404,1444,2464,3464,4451,0761,1171,1021,1391,0941,1481,1901,2361,2811,3471,4901,5161,6191,7451,8792,0142,1482,3202,4562,5962,7350003,308
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,687
0
0
1,030
7,161
0
0
0
0
0
0
0
0
0
0000000007,1611,0300018,687000000000000000000000000000000
       Long-term Assets Other 
0
0
0
0
2,605
1,464
3,087
144
144
144
144
144
144
144
165
165
165
165
165
165
394
355
355
355
355
355
355
355
105
105
105
105
105
740
105
571
613
601
107
108
105
105
105
105
1051051051051081076016135711057401051051051051053553553553553553553553941651651651651651651441441441441441441443,0871,4642,6050000
> Total Liabilities 
5,546
0
0
0
62,594
7,613
33,605
4,693
4,472
4,208
5,216
4,125
5,186
6,174
8,439
27,328
18,112
18,198
14,205
19,658
18,996
30,650
44,112
41,578
27,331
12,463
11,729
13,224
19,464
17,820
53,432
41,599
38,496
34,725
29,373
24,837
17,386
26,042
27,913
26,137
32,531
23,689
20,360
14,884
14,88420,36023,68932,53126,13727,91326,04217,38624,83729,37334,72538,49641,59953,43217,82019,46413,22411,72912,46327,33141,57844,11230,65018,99619,65814,20518,19818,11227,3288,4396,1745,1864,1255,2164,2084,4724,69333,6057,61362,5940005,546
   > Total Current Liabilities 
4,715
0
0
0
7,117
7,613
13,453
4,289
4,159
3,683
4,694
3,729
3,769
4,931
7,259
6,422
4,418
4,427
3,631
2,930
4,421
3,923
4,722
5,440
5,797
5,943
3,910
7,660
10,058
8,904
5,894
4,828
6,060
7,940
7,960
9,870
12,174
16,564
20,600
23,783
20,840
19,652
16,473
12,323
12,32316,47319,65220,84023,78320,60016,56412,1749,8707,9607,9406,0604,8285,8948,90410,0587,6603,9105,9435,7975,4404,7223,9234,4212,9303,6314,4274,4186,4227,2594,9313,7693,7294,6943,6834,1594,28913,4537,6137,1170004,715
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
622
626
629
632
635
638
641
645
648
651
654
657
661
664
667
671
674
677
680
6806776746716676646616576546516486456416386356326296266220000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
622
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000006220000000000000000000000000
       Accounts payable 
2,246
0
0
0
2,125
1,753
1,784
389
482
951
1,338
940
1,517
1,821
4,216
3,875
1,550
3,018
1,961
1,235
1,302
1,521
1,095
2,509
1,427
3,162
1,252
4,374
2,622
6,635
3,019
2,191
1,806
3,872
3,055
2,964
2,389
8,267
11,269
15,348
13,671
10,828
11,557
8,179
8,17911,55710,82813,67115,34811,2698,2672,3892,9643,0553,8721,8062,1913,0196,6352,6224,3741,2523,1621,4272,5091,0951,5211,3021,2351,9613,0181,5503,8754,2161,8211,5179401,3389514823891,7841,7532,1250002,246
       Other Current Liabilities 
1,399
0
0
0
4,992
5,860
11,669
3,900
3,677
2,731
3,356
2,789
2,252
3,110
3,044
2,547
2,868
1,409
1,670
1,694
3,118
2,402
3,627
2,932
4,370
2,159
2,033
2,657
6,804
1,634
2,237
1,996
3,610
3,420
4,254
6,252
9,128
7,636
8,667
7,768
6,498
8,150
4,239
3,464
3,4644,2398,1506,4987,7688,6677,6369,1286,2524,2543,4203,6101,9962,2371,6346,8042,6572,0332,1594,3702,9323,6272,4023,1181,6941,6701,4092,8682,5473,0443,1102,2522,7893,3562,7313,6773,90011,6695,8604,9920001,399
   > Long-term Liabilities 
0
0
0
0
55,477
0
20,151
404
313
525
521
396
1,416
1,243
1,180
20,906
13,693
13,771
10,575
16,728
14,575
26,727
39,390
36,138
21,534
6,520
7,819
5,565
9,406
8,917
47,538
36,771
32,436
26,785
21,413
14,967
5,212
9,478
7,313
2,354
11,691
4,037
3,887
2,561
2,5613,8874,03711,6912,3547,3139,4785,21214,96721,41326,78532,43636,77147,5388,9179,4065,5657,8196,52021,53436,13839,39026,72714,57516,72810,57513,77113,69320,9061,1801,2431,41639652152531340420,151055,4770000
       Long term Debt Total 
0
0
0
0
0
0
14,502
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000014,502000000
       Warrants
0
0
0
0
0
0
40,392
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000040,392000000
       Other Liabilities 
0
0
0
0
5,769
6,207
7,796
403
313
525
522
397
1,416
1,243
1,180
20,906
13,693
13,771
10,574
16,728
14,575
26,727
39,390
36,138
21,534
3,055
4,419
2,232
6,142
5,726
44,423
33,733
32,436
23,910
18,625
12,267
2,603
6,815
4,899
-49
9,481
0
1,899
0
01,89909,481-494,8996,8152,60312,26718,62523,91032,43633,73344,4235,7266,1422,2324,4193,05521,53436,13839,39026,72714,57516,72810,57413,77113,69320,9061,1801,2431,4163975225253134037,7966,2075,7690000
       Deferred Long Term Liability 
0
0
0
0
0
0
5,649
404
313
525
521
396
1,416
1,243
1,180
20,906
13,693
13,771
10,575
16,728
14,254
26,520
39,317
36,065
21,461
0
4,346
2,159
6,069
5,653
44,350
33,660
29,404
23,837
18,552
12,194
2,530
6,742
0
0
0
0
0
0
0000006,7422,53012,19418,55223,83729,40433,66044,3505,6536,0692,1594,346021,46136,06539,31726,52014,25416,72810,57513,77113,69320,9061,1801,2431,4163965215253134045,649000000
> Total Stockholder Equity
7,660
0
0
0
-52,911
1,071
-25,620
29,509
25,582
21,102
33,127
28,171
30,676
22,861
13,772
18,545
19,513
13,551
11,088
35,466
31,193
12,512
-7,159
-701
5,542
17,484
9,188
4,219
15,545
8,609
14,274
18,397
12,620
61,905
57,434
53,005
49,376
29,998
12,885
-3,103
-11,852
-3,137
-1,108
-5,759
-5,759-1,108-3,137-11,852-3,10312,88529,99849,37653,00557,43461,90512,62018,39714,2748,60915,5454,2199,18817,4845,542-701-7,15912,51231,19335,46611,08813,55119,51318,54513,77222,86130,67628,17133,12721,10225,58229,509-25,6201,071-52,9110007,660
   Common Stock
0
0
0
0
0
1
0
2
2
2
3
3
3
3
3
4
4
4
4
7
7
7
7
8
8
8
8
8
2
2
3
3
3
4
4
4
4
4
4
4
1
1
1
1
11114444444333228888877774444333332220100000
   Retained Earnings Total Equity000000-280,709-260,552-256,153-250,861-245,465-240,270-233,866-237,310-219,693-212,114-201,759-196,400-187,733-199,320-205,256-200,878-180,742-161,635-156,878-155,303-152,466-146,118-146,712-136,182-126,503-117,579-109,991-104,427-97,310-92,458-87,722-71,324000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-1,257
0
0
-34,201
-1
-48
-76
-84
-30
-2
3
-39
-52
-46
-19
-24
-75
-92
-44
-19
-30
1
2
0
-3,247
9
-7
-8
-21
-29
-42
-43
-84
-224
-213
-140
-32
0
0
0
000-32-140-213-224-84-43-42-29-21-8-79-3,247021-30-19-44-92-75-24-19-46-52-393-2-30-84-76-48-1-34,20100-1,2570000
   Capital Surplus 
0
0
0
0
0
0
5,311
117,229
118,039
118,459
137,627
138,244
148,283
149,363
149,948
165,292
165,678
166,059
166,406
192,360
192,896
193,338
193,756
204,566
204,884
205,208
205,578
205,970
227,658
228,291
251,588
252,268
252,908
307,395
308,333
309,197
310,008
310,927
0
0
0
0
0
0
000000310,927310,008309,197308,333307,395252,908252,268251,588228,291227,658205,970205,578205,208204,884204,566193,756193,338192,896192,360166,406166,059165,678165,292149,948149,363148,283138,244137,627118,459118,039117,2295,311000000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
4,930
72,772
5,311
117,229
118,039
118,459
137,627
138,244
148,283
149,363
149,948
165,292
165,678
166,059
166,406
192,360
192,896
193,338
193,756
204,566
204,884
205,208
205,578
205,970
227,658
228,291
251,588
252,268
252,908
307,395
308,333
309,197
310,008
310,927
311,892
312,898
313,884
323,938
333,535
334,243
334,243333,535323,938313,884312,898311,892310,927310,008309,197308,333307,395252,908252,268251,588228,291227,658205,970205,578205,208204,884204,566193,756193,338192,896192,360166,406166,059165,678165,292149,948149,363148,283138,244137,627118,459118,039117,2295,31172,7724,9300000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-30,214
Operating Income-30,214-30,214
 
Operating Expense (+$)
Research Development18,473
Selling General Administrative11,741
Selling And Marketing Expenses-
Operating Expense30,21430,214
 
Net Interest Income (+$)
Interest Income327
Interest Expense--
Other Finance Cost-0
Net Interest Income327
 
Pretax Income (+$)
Operating Income-30,214
Net Interest Income327
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-24,138-35,963
EBIT - interestExpense = 0
-24,138
-24,138
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--24,138
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-24,138
Tax Provision--
Net Income From Continuing Ops-24,138-24,138
Net Income-24,138
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net5,749-327
 

Technical Analysis of Contrafect
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Contrafect. The general trend of Contrafect is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Contrafect's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ContraFect Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.0399 < 0.0399 < 0.0399.

The bearish price targets are: 0.0261 > 0.0261 > 0.025.

Tweet this
ContraFect Corp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ContraFect Corp. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ContraFect Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ContraFect Corp. The current macd is -0.00502021.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Contrafect price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Contrafect. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Contrafect price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
ContraFect Corp Daily Moving Average Convergence/Divergence (MACD) ChartContraFect Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ContraFect Corp. The current adx is 9.20579791.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Contrafect shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
ContraFect Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ContraFect Corp. The current sar is 0.037604.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
ContraFect Corp Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ContraFect Corp. The current rsi is 39.68. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
ContraFect Corp Daily Relative Strength Index (RSI) ChartContraFect Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ContraFect Corp. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Contrafect price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
ContraFect Corp Daily Stochastic Oscillator ChartContraFect Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ContraFect Corp. The current cci is -101.02942516.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
ContraFect Corp Daily Commodity Channel Index (CCI) ChartContraFect Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ContraFect Corp. The current cmo is -18.25140824.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
ContraFect Corp Daily Chande Momentum Oscillator (CMO) ChartContraFect Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ContraFect Corp. The current willr is -76.19047619.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Contrafect is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
ContraFect Corp Daily Williams %R ChartContraFect Corp Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ContraFect Corp.

ContraFect Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ContraFect Corp. The current atr is 0.00802981.

ContraFect Corp Daily Average True Range (ATR) ChartContraFect Corp Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ContraFect Corp. The current obv is 225,473,608.

ContraFect Corp Daily On-Balance Volume (OBV) ChartContraFect Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ContraFect Corp. The current mfi is 33.39.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
ContraFect Corp Daily Money Flow Index (MFI) ChartContraFect Corp Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ContraFect Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-09-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2023-09-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-10-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-10-11MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-10-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-10-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-10-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-10-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-10-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-10-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-31RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

ContraFect Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ContraFect Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.685
Ma 20Greater thanMa 500.032
Ma 50Greater thanMa 1000.037
Ma 100Greater thanMa 2000.196
OpenGreater thanClose0.030
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Contrafect with someone you think should read this too:
  • Are you bullish or bearish on Contrafect? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Contrafect? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ContraFect Corp

I send you an email if I find something interesting about ContraFect Corp.


Comments

How you think about this?

Leave a comment

Stay informed about ContraFect Corp.

Receive notifications about ContraFect Corp in your mailbox!